Holoclar for treating limbal stem cell deficiency after eye burns

  • Technology appraisal guidance
  • TA467
  • Published: 
Download guidance (PDF)

Update information

September 2020: Section 2 of the guidance updated because the marketing authorisation holder changed from Chiesi Farmaceutici to Holostem Terapie Avanzate. The company contact details were removed from section 5 and updated details put on the overview page for the guidance.

Information in tables was presented in a different way, to meet accessibility requirements.

ISBN: 978-1-4731-2628-2

  • National Institute for Health and Care Excellence (NICE)